ImmunityBio Inc.

ImmunityBio Inc.

World Rank (Jan-05-2024)
4,154
Market Cap (Jan-05-2024)
3.225 Billion USD
World Rank (Jul-30-2023)
8,650
Market Cap (Jul-30-2023)
1.016 Billion USD
World Rank (Jan-07-2022)
5,471
Market Cap (Jan-07-2022)
2.502 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
IBRX
Market Cap (Mar-08-2026)
8.91
Employee Count
587
Employee Count as of Date
As on 2021
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-350 Million USD
Annual Net Income in USD
-416 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
362 Million USD
Total Liabilities in USD
812 Million USD
Total Equity in USD
-449 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Company Website
IMMUNITYBIO, INC.
Company Profile
ImmunityBio is a Late Clinical Stage Immunotherapy company for treating cancer and infectious diseases. The headquarters is in USA.
Founded Year
2014
IPO Year
2015
Stock Exchange
Frankfurt
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Biological Products (No Diagnostic Substances)

Share